AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 06, 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Announced exclusive option and license agreement with Takeda for ACI-24.060 on May 13 for $100 million upfront...
Allbirds Announces Agreement with Belle Fashion Group in China
August 02, 2024 07:00 ET
|
Allbirds, Inc.
SAN FRANCISCO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Allbirds Inc., a global lifestyle brand that innovates with naturally derived materials to make better products in a better way, announced that Belle...
Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
August 01, 2024 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it completed the sale of its EndoPredict®...
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
August 01, 2024 06:00 ET
|
Instil Bio
DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced...
InterDigital signs license agreement with Panasonic
August 01, 2024 04:30 ET
|
InterDigital, Inc.
WILMINGTON, Del., Aug. 01, 2024 (GLOBE NEWSWIRE) -- InterDigital, Inc. (Nasdaq: IDCC), a mobile, video and AI technology research and development company, today announced it has signed a new license...
Valneva et LimmaTech signent un partenariat stratégique pour accélérer le développement du candidat vaccin tétravalent contre la shigellose le plus avancé au monde
August 01, 2024 01:00 ET
|
VALNEVA
Valneva obtient une licence exclusive mondiale pour le candidat vaccin contre la Shigellose S4V de LimmaTech et ajoute un actif de Phase 2 attractif à son portefeuille de R&D LimmaTech recevra un...
Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
August 01, 2024 01:00 ET
|
VALNEVA
Valneva obtains exclusive worldwide license for LimmaTech’s S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva’s R&D pipeline LimmaTech to receive upfront...
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
July 30, 2024 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, July 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative...
Dragonfly Energy Enters into $30M Licensing Agreement for Battle Born Batteries Brand with Stryten Energy, a Leading North American Battery Manufacturer
July 30, 2024 08:00 ET
|
Dragonfly Energy Holdings Corp.
Dragonfly Energy signs a $30 million agreement to license its popular lithium-ion battery brand, Battle Born Batteries®, to Stryten Energy for distribution globally Stryten Energy will have exclusive...
Aphria RX von Tilray erhält Cannabis Trading-Lizenz in Deutschland und erweitert damit die kommerziellen Wachstumschancen beträchtlich
July 29, 2024 18:03 ET
|
Tilray Brands, Inc.
NEUMÜNSTER, Deutschland, July 30, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. („Tilray“) (Nasdaq: TLRY; TSX: TLRY), ein weltweit führendes Unternehmen im Bereich der Forschung, des Anbaus, der...